RT Journal Article
SR Electronic
T1 The association between clonal hematopoiesis driver mutations, immune cell function and the vasculometabolic complications of obesity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.07.23292396
DO 10.1101/2023.07.07.23292396
A1 Tercan, Helin
A1 Cossins, Benjamin
A1 van Deuren, Rosanne
A1 Rutten, Joost H.W.
A1 Joosten, Prof. Leo A.B.
A1 Netea, Prof. Mihai G.
A1 Hoischen, Alexander
A1 Bekkering, Siroon
A1 Riksen, Prof. Niels P.
YR 2023
UL http://medrxiv.org/content/early/2023/07/08/2023.07.07.23292396.abstract
AB Background Obesity is accompanied by dysregulated inflammation, which can contribute to vasculometabolic complications, including metabolic syndrome and atherosclerosis. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular diseases. We aimed to determine how CHIP related to immune cell function, systemic inflammation, and vasculometabolic complications in obese individuals.Methods 297 individuals with overweight and obesity, between the ages of 54 and 81, were recruited in a cross-sectional study. Clonal Hematopoiesis Driver Mutations (CHDMs) were identified with an ultrasensitive targeted assay. Assesment of carotid artery atherosclerosis was performed with ultrasound. Detailed immunological parameters were studied. Adipose tissue inflammation was determined in subcutenous fat biopsies.Results Individuals with CHIP had higher concentrations of circulating IL-6. Total number of leukocytes and neutrophils were higher in individuals with CHIP. In contrast, ex vivo cytokine production capacity of PBMCs was significantly lower in individuals with CHIP. Sex stratified analysis showed that men with CHDMs had significantly higher leukocyte and neutrophil counts and ex vivo cytokine production capacity was lower in women with CHDMs. Surprisingly, the presence of atherosclerotic plaques was significantly lower in individuals with CHDMs. There was no relation between CHIP and metabolic syndrome.Conclusion In individuals with overweight or obesity, CHDMs are not associated with vasculometabolic complications, but rather with a lower presence of carotid plaques. CHDMs associate with increased circulating inflammatory markers and leukocyte numbers, but a lower PBMC cytokine production capacity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNPR, MGN, and LABJ received a CVON grant from the Dutch Cardiovascular Alliance (DCVA) and Dutch Heart Foundation (CVON2018-27; IN CONTROL II). NPR was recipient of a grant of the ERA-CVD Joint Transnational Call 2018 supported by the Dutch Heart Foundation (JTC2018, project MEMORY; 2018T093) SB is supported by the Dutch Heart Foundation (2018T028). M.G.N was supported by an ERC Advanced Grant (#833247) and a Spinoza grant of the Netherlands Organization for Scientific Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research protocol was approved by the Radboud University Ethical Committee (nr. 46846.091.13), and all subjects gave written informed consent. The study protocol was performed in accordance with the 1975 Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicablePart of the data is publically available on the website of Human Functional Genomics Project (HFGP (bbmri.nl)), the rest is available upon reasonable request to the HFGP committee.CHIPClonal Hematopoiesis of Indeterminate PotentialCHDMClonal Hematopoiesis Driver MutationVAFVariant Allele FrequencyPWVPulse Wave VelocityAIAugmentation IndexNLRNeutrophil-to-lymphocyte ratioDNMT3ADNA methyltransferase 3aTET2tet methylcytosine dioxygenase 2